Clinical Trial: ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07109531) titled 'ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy' on July 31.

Brief Summary: This study is designed to compare the safety and efficacy of ASKC202 combined with Limertinib Versus platinum-based chemotherapy in locally advanced or metastatic NSCLC With MET Amplification/Overexpression after disease progression on EGFR tyrosine kinase inhibitor.

Study Start Date: Aug. 31

Study Type: INTERVENTIONAL

Condition: Locally Advanced or Metastatic NSCLC

Intervention: DRUG: ASKC202+ Limertinib

ASKC...